Get started

INDOCO

INDOCO | Positional Trade📊 DETAILS Sector: Pharmaceuticals & Drugs Mkt Cap: 3,746 cr Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations with a presence in contract manufacturing and research. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). TTM PE : 33.03 (Average PE) Sector PE : 51.38 Beta : 0.64 📚 INSIGHTS Mid-range performer Stock with medium financial performance with average price momentum and valuation. These stocks may be affordable and are showing some investors interest. 2.04% away from 52 week high Outperformer - Indoco Remedies up by 7.17% v/s NIFTY 50 up by 1.99% in last 1 month 📈 FINANCIALS Piotroski Score of 5/9 indicates Average Financials Disclaimer: This analysis is for educational purposes only, and I'm not a SEBI registered analyst. If you found this analysis helpful, I encourage you to like and share it. Your observations and comments are also welcomed below. Your support, likes, follows, and comments motivate me to consistently share valuable insights with you. 🔍 More Analysis & Trade Setups 🔍 For more technical analysis and trade setups, make sure to follow me on TradingView: www.tradingview.com
NSE:INDOCOLong
by Munish_Jain
Indoco Remedies Ltd |A Sector Rotation (Pharmaceutical)Indoco Remedies Ltd |A Sector Rotation (Pharmaceutical) Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations with a presence in contract manufacturing and research. Market Cap = ₹ 3,758 Cr. Dividend Yield=0.55 % ROCE=17.4 % ROE =14.8 % Debt to equity = 0.46 Promoter holding = 58.7 % Quick ratio = 1.13 Current ratio = 1.76 Piotroski score = 5.00 Profit Var 3Yrs = 80.6 % Sales growth 3Years = 14.7 % Pledged percentage = 0.00 % Return on assets = 9.11 % Indoco Remedies Limited is now in momentum zone I just analyses chart and as per my view I shared my entry exit and tgt please do your research before investing. if you like my idea than like and boost and follow me for more ideas. thanks.
NSE:INDOCOLong
by Momentuminvesting5540
INDOCO review: up till now, from 345 to 394, & yet more to comereviewing NSE:INDOCO chart posted on 11th Aug 2023 when the price was 345 thereafter it made high of 404.70 and now trading at 394 giving excellent 14% gains till now more gains to come in coming months This analysis is being done for educational and knowledge-sharing purposes. This article does not offer any kind of buy or sell advice. All stocks are positional and are held for a short to medium period of time. Everyone is expected to conduct their own research and analysis to determine whether my point of view align with your study. link of 11th Aug 2023 post given below
NSE:INDOCOLong
by ajaykalashi
INDOCO REMEDIES - Medium Term StudyChart Structure: - Broken out All-Time High (of 2015), pulled back, consolidated a bit, and now ready to go up. - Price in an uptrend since July 2020. Volume: - High volume deliveries this week. Up to 12.41 lac shares were delivered yesterday, whereas average deliveries are 1.23 lacs. - Yesterday saw the highest delivery of shares in recent times. Relative Strength: - Stock become RS+ on 19th April and continuously outperforming Nifty as well as Midcap since then. - Spread chart breakout happened yesterday. Financial Highlights: - Net Revenues saw 29.3% jump in QoQ & 43% YoY. - PAT increased by 59% QoQ & 130% YoY. - Co. is continuously increasing its revenues & profits at a medium pace, which tells us the financial health of the company is sound. - Indoco's Defensive & Enterprises EPS are also been positive throughout the years, which tells us that the company is able to sustain itself without taking any more debts & they are able to monetize their current expenditures for next few years. About Indoco: About Indoco Remedies Limited: Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with a presence in 55 countries. Indoco, a USD 166 million Company, employs over 6000 people including more than 300 skilled scientists. The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from over 3,00,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments. Indoco has tie-ups with large generic companies across the globe.
NSE:INDOCOLong
by AmanSaraf